Will crystal Parkin help in understanding the future of Parkinson’s disease?

Diana Angelika Olszewska* and Tim Lynch

Department of Neurology, Dublin Neurological Institute, Mater Misericordiae University Hospital, Dublin, Ireland

*Correspondence: diana.angelika.olszewska@gmail.com

Edited by:
Alberto J. Espay, University of Cincinnati, USA

Reviewed by:
Renato Puppi Munhoz, Pontifical Catholic University of Parana, Brazil
Sheila Fleming, University of Cincinnati, USA
Kim Seroogy, University of Cincinnati, USA

Keywords: parkinsonism, crystal structure, crystal parkin, RING structure, E3 ligase

A commentary on

Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases

by Riley BE, Loughheed JC, Callaway K, Velasquez M, Brecht E, Nguyen L, et al.

Nature Communications the first crystal structure of Parkin and described the molecule at the atomic level (5). Parkin is a canonical RING-between-RING (RBR) E3 ligase (Figure 1). E3 ligases have a crucial role in the final step of ubiquitination by transferring ubiquitin from E2 enzyme to lysine substrate (6). Studies suggest that RBR ligases may contain a catalytic cysteine residue, similarly to HECT ligases (E3 enzymes influencing specificity of ubiquitylation). The organization of domains, exact residues, and regulation of ligase activity remains elusive. Parkin is activated through phosphorylation of ubiquitin by PINK1 (do not forget that mutations in PINK1 are also associated with autosomal recessive PD). Parkin is a folded-in-half molecule consisting of ubiquitin-like domain (UBL), followed by four RING domains, each bonded to two Zn atoms (3) (Figure 1). RING0 (also called a unique Parkin domain-UPD) (4) at the N-terminal end is an innovative structure resembling zinc-finger domain. RING1-IBR (in between ring) domains are spatially opposite RING2. Parkin has a unique RING0:RING2 (C-terminal) bond which may alter Parkin’s active control site demonstrated by mass spectrometry to be at catalytic cysteine 431 (C431) (Figure 1).

Simultaneously, Trempe et al. (2) confirmed these findings and similarly described how RING0 occludes the active site (C431) in RING2, while a flexible IBR-R2 linker (tether) residue (repressor element of Parkin-REP or W403) sits in a pocket on RING1 and may anchor the tether to RING1 and block the E2-binding site (Figure 1). The interface has two compact domains separated by two linkers: (1) RING1–IBR containing E2-binding site and (2) RING0–RING2 with the C431 active site (5).

The discovery of the crystal structure of Parkin provides new opportunities for defining (1) the molecular function of Parkin’s target site, (2) the binding of possible therapeutic particles, (3) the mechanism of action of Parkin, and (4) the modulation/enhancement of novel drug molecules (7). For example, mutations of the C431 active site cause loss of the Parkin mitochondrial degradation mechanism (5), whereas deletion of RING0 (lack of occlusion of C431 as described) causes increased C431 reactivity and Parkin auto ubiquitination (3). Deletion of UBL domain with/without the linker has little effect on Parkin activity (2). Mutations in hydrophobic residues of RING0:RING2 interface increase auto ubiquitination (5).

Crystal structure research and discovery has increased our understanding about lysozyme function, vitamin B12 action, penicillin, and its modifications (7, 8) and has been used in the discovery of the new treatments for glaucoma (dorzolamide), HIV (protease inhibitors: saquinavir, indinavir, ritonavir, and nelfinavir) (9), and chronic myelogenous leukemia (tyrosinase-kinase inhibitor- Imatinib) (10). It has also clarified the mechanism of leukemic drug resistance (11) and is currently relevant to HIV1 research with the development of reverse transcriptase capable of the rapid crystallization, which will help the design of new anti-AIDS medications (12).
In summary, Johnston group have improved our understanding of the Parkin structure at the atomic level with the discovery of its crystal structure. Mapping of Parkin mutations affecting the stability of the molecule (mutations in Zn), catalytic reactions (active site at C431), and the interactions among domains (E2-binding site) (3, 4) may help future drug development in PD and neurodegeneration by enhancing activity at the active site or by understanding further its molecular interactions.

AUTHOR CONTRIBUTIONS
DO: writing first draft and corrections. TL: review and critique.

REFERENCES
1. Bonifati V. Genetics of Parkinson’s disease-state of the art, 2013. Parkinsonism Relat Disord (2014) 20(Suppl 1):S23–8. doi:10.1016/S1353-8020(13)70009-9
2. Trempe JF, Sauvé V, Grenier K, Seirafi M, Tang MY, Ménade M, et al. Structure of Parkin reveals mechanisms for ubiquitin ligase activation. Science (2013) 340:1451–5. doi:10.1126/science.1237908
3. Byrd RA, Weissman AM. Compact Parkin only: insights into the structure of an autoinhibited ubiquitin ligase. EMBO J (2013) 32(15):2087–9. doi:10.1038/emboj.2013.158
4. Waier T, Komander D. Structure of the human Parkin ligase domain in an autoinhibited state. EMBO J (2013) 32(15):2099–112. doi:10.1038/emboj.2013.125
5. Riley BE, Lougheed JC, Callaway K, Velsaquez M, Brecht E, Nguyen L, et al. Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat Commun (2013) 4:1982. doi:10.1038/ncomms2982
6. Berndsen CE, Wolberger C. New insights into ubiquitin E3 ligase mechanism. Nat Struct Mol Biol (2014) 21(4):301–7. doi:10.1038/nsmb.2786
7. Blake CCF, Koenig DF, Mair GA, North ACT, Philips DC, Sarma VR, et al. Structure of hen egg-white lysozyme: a three-dimensional Fourier synthesis at 2 Å resolution. Nature (1965) 206(4986):757–61. doi:10.1038/206757a0
8. Crowfoott Hodgkin D, Pickworth J, Robertson JH, Trueblood K, Prosen R, White J. Structure of vitamin B12: the crystal structure of the hexacarboxylic acid derived from B12 and the molecular structure of the vitamin. Nature (1955) 176:325–8. doi:10.1038/176325a0
9. Kubini H. Structure-based design of enzyme inhibitors and receptor ligands. Curr Opin Drug Discov Devel (1998) 1(1):4–15.
10. Maynes JT. The role of protein structure in rational drug design and pharmaceutical development. Univ Alberta Health Sci J (2004) 1(1):7–8.
11. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science (2004) 303:1800–5. doi:10.1126/science.1095920
12. Bauman JD, Kahan D, Ho WC, Brazda M, Himmel DM, Clark AD Jr, et al. Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Nucleic Acids Res (2008) 36(15):5083–92. doi:10.1093/nar/gkn464

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 21 November 2014; accepted: 12 February 2015; published online: 24 February 2015. Citation: Olszewska DA and Lynch T (2015) Will crystal Parkin help in understanding the future of Parkinson’s disease? Front. Neurol. 6:35. doi:10.3389/fneur.2015.00035

This article was submitted to Movement Disorders, a section of the journal Frontiers in Neurology. Copyright © 2015 Olszewska and Lynch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.